|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
146,000,000 |
Market
Cap: |
15.09(B) |
Last
Volume: |
1,597,388 |
Avg
Vol: |
1,336,304 |
52
Week Range: |
$92.79 - $210.56 |
|
Level
I Sector: |
Information Technology |
Level
II Sector: |
Electronics |
Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : 11.4 |
Insider 3/6 Months : 12 |
|
Guru Rank Number : 691 |
Guru Rank Value : 2.3 |
Guru Occurances : 3 |
|
|
|
|
|
|
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
7,330 |
7,330 |
7,330 |
Total Buy Value |
$0 |
$991,672 |
$991,672 |
$991,672 |
Total People Bought |
0 |
1 |
1 |
1 |
Total Buy Transactions |
0 |
1 |
1 |
1 |
Total Shares Sold |
0 |
0 |
1,815 |
22,740 |
Total Sell Value |
$0 |
$0 |
$314,105 |
$4,648,975 |
Total People Sold |
0 |
0 |
2 |
3 |
Total Sell Transactions |
0 |
0 |
4 |
17 |
End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Pegels Kevin Carl |
Chief of Global Operations |
|
2022-02-22 |
4 |
D |
$319.86 |
$123,466 |
D/D |
(386) |
5,524 |
|
- |
|
Pegels Kevin Carl |
Chief of Global Operations |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,065 |
5,910 |
|
- |
|
Samad Samer Abdul |
SVP and CFO |
|
2022-02-22 |
4 |
D |
$319.86 |
$578,307 |
D/D |
(1,808) |
9,215 |
|
- |
|
Samad Samer Abdul |
SVP and CFO |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,561 |
11,023 |
|
- |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2022-02-22 |
4 |
D |
$319.86 |
$320,500 |
D/D |
(1,002) |
4,864 |
|
- |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,851 |
5,866 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2022-02-22 |
4 |
D |
$319.86 |
$578,307 |
D/D |
(1,808) |
42,083 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,561 |
43,891 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2022-02-22 |
4 |
D |
$319.86 |
$578,307 |
I/I |
(1,808) |
6,081 |
|
- |
|
Dadswell Charles |
SVP & General Counsel |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
I/I |
4,561 |
7,889 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2022-02-22 |
4 |
D |
$319.86 |
$2,924,800 |
D/D |
(9,144) |
79,443 |
|
- |
|
Desouza Francis A |
President and CEO |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,383 |
88,587 |
|
- |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2022-02-22 |
4 |
D |
$319.86 |
$301,948 |
D/D |
(944) |
5,734 |
|
- |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,421 |
6,678 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2022-02-22 |
4 |
D |
$319.86 |
$486,507 |
D/D |
(1,521) |
6,303 |
|
- |
|
Goswami Joydeep |
SVP Corp Business Development |
|
2022-02-22 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,979 |
7,824 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2022-01-12 |
4 |
AS |
$425.00 |
$340,000 |
D/D |
(800) |
39,274 |
|
-41% |
|
Hoyt Aimee L |
SVP, Chief People Officer |
|
2022-01-08 |
4 |
D |
$362.28 |
$41,662 |
D/D |
(115) |
3,208 |
|
- |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-12-28 |
4 |
AS |
$387.06 |
$38,706 |
D/D |
(100) |
40,074 |
|
-34% |
|
Dadswell Charles |
SVP & General Counsel |
|
2021-12-22 |
4 |
AS |
$380.29 |
$122,453 |
I/I |
(322) |
3,283 |
|
-21% |
|
Tousi Susan H |
SVP, Chief Commercial Officer |
|
2021-12-08 |
4 |
AS |
$375.00 |
$37,500 |
D/D |
(100) |
40,174 |
|
-8% |
|
Dadswell Charles |
SVP, General Counsel |
|
2021-11-22 |
4 |
AS |
$377.86 |
$118,648 |
I/I |
(314) |
3,605 |
|
-4% |
|
Febbo Phillip G. |
SVP Chief Medical Officer |
|
2021-11-08 |
4 |
AS |
$406.83 |
$406,830 |
D/D |
(1,000) |
3,015 |
|
-13% |
|
Desouza Francis A |
President and CEO |
|
2021-11-05 |
4 |
D |
$408.14 |
$1,470,937 |
D/D |
(3,604) |
69,150 |
|
- |
|
Aravanis Alexander |
SVP, Chief Technology Officer |
|
2021-11-05 |
4 |
D |
$408.14 |
$77,955 |
D/D |
(191) |
4,488 |
|
- |
|
3467 Records found
|
|
Page 7 of 139 |
|
|